CRSP - CRISPR Therapeutics AG -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date: October 19, 2016
Sector: Healthcare
Industry: Biotech
Market Cap: $4.88B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.76 | 3.05%
Avg Daily Range (30 D): $1.20 | 2.15%
Avg Daily Range (90 D): $1.36 | 2.51%
Institutional Daily Volume
Avg Daily Volume: 1.22M
Avg Daily Volume (30 D): 1.33M
Avg Daily Volume (90 D): 1.4M
Trade Size
Avg Trade Size (Sh.): 61
Avg Trade Size (Sh.) (30 D): 54
Avg Trade Size (Sh.) (90 D): 53
Institutional Trades
Total Institutional Trades: 9,591
Avg Institutional Trade: $2.35M
Avg Institutional Trade (30 D): $3.19M
Avg Institutional Trade (90 D): $3.11M
Avg Institutional Trade Volume: .04M
Avg Institutional Trades (Per Day): 4
Market Closing Trades
Avg Closing Trade: $5.92M
Avg Closing Trade (30 D): $12.11M
Avg Closing Trade (90 D): $10.61M
Avg Closing Volume: 95.78K
 
News
Oct 8, 2026 @ 2:47 PM
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy...
Source: Na
Oct 8, 2026 @ 1:49 PM
Ultragenyx to Sell Rare Pediatric Disease PRV for ...
Source: Na
Oct 6, 2026 @ 8:50 PM
CRISPR Therapeutics AG (CRSP) Stock Slides as Mark...
Source: Zacks.Com
Sep 29, 2026 @ 12:00 PM
CRISPR Therapeutics AG (CRSP) is Attracting Invest...
Source: Zacks.Com
Sep 16, 2026 @ 5:00 PM
Hypertension Clinical Trial Pipeline Accelerates a...
Source: Delveinsight
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-4.74 $-.94 $-1.28
Diluted EPS $-4.74 $-.94 $-1.28
Revenue $13.39M $10.18M $1.46M
Gross Profit
Net Income / Loss $-451.14M $-91.15M $-122.93M
Operating Income / Loss $-534.34M $-117.27M $-130.25M
Cost of Revenue
Net Cash Flow $94.26M $-131.98M $72.27M
PE Ratio